Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:administered_by |
subcutaneous injection
|
| gptkbp:approves |
gptkb:2015
gptkb:FDA |
| gptkbp:class |
PCSK9 inhibitor
|
| gptkbp:developed_by |
gptkb:Sanofi
|
| https://www.w3.org/2000/01/rdf-schema#label |
Alirocumab
|
| gptkbp:mechanism_of_action |
inhibits PCSK9 protein
|
| gptkbp:targets |
gptkb:PCSK9
|
| gptkbp:trade |
gptkb:Praluent
|
| gptkbp:used_for |
hyperlipidemia
|
| gptkbp:bfsParent |
gptkb:PCSK9_inhibitors
|
| gptkbp:bfsLayer |
7
|